"NEW CONNECTIONS PLEASE INTRODUCE YOURSELF if we haven't worked together. For new cold calling connections, I'm happy to connect here if you explain how can we add value to eachother. I understand the need for "cold calling", but I don't have time or interest. Sorry"As a highly accomplished pharmaceutical physician with over 16 years of experience, I have designed and executed clinical and drug development programs for pharma and biotech companies. My expertise lies in haematological malignancies and solid tumors, and I have been instrumental in driving the successful development and launch of multiple biologics, small molecules, and cell therapy products. My experience in cell and gene therapy is noteworthy, as I played a critical role in the development of Yescarta, a revolutionary CAR-T therapy for the treatment of aggressive and indolent lymphoma patients and Tecartus in mantle cell lymphoma. I also served as the global medical lead for the ZUMA-1 development program and the European medical lead for the ZUMA-5 and ZUMA-2 programs for Tecartus. I was instrumental in the submission and approval of multiple biological license applications for Yescarta and Tecartus, bringing life-saving therapies to patients.My therapeutic area expertise includes non-Hodgkin's Lymphoma, small and non-small cell lung cancer, multiple myeloma, acute myeloid leukemia and chronic lymphocytic leukemia, urothelial and cholangiocarcinoma, ovarian cancer, gastric, esophageal and colorectal cancer, and renal cell carcinoma. I have a proven track record in designing and implementing robust protocols and clinical databases to facilitate successful clinical trials across Phase I-IV.In my previous roles as a clinical development consultant and Chief Medical Officer, I have successfully led the development and execution of clinical development programs for multiple pharmaceutical and biotech companies. My key role in the approval of multiple new indications and line extensions for a range of oncology and haematology therapies demonstrates my expertise in BLA, NDA, and MAA submissions.One of my proudest accomplishments has been setting up Early Access to Medicine Scheme (EAMS) processes for multiple clients. These efforts have resulted in more than 15 EAMS approvals across oncology, hematology, and rare diseases.